What is Global Buprenorphine Hydrochloride Market?
The Global Buprenorphine Hydrochloride Market is a vast and complex field that encompasses a variety of aspects. Buprenorphine Hydrochloride is a semi-synthetic opioid that is used to treat opioid addiction in higher dosages, to control moderate acute pain in non-opioid-tolerant individuals in lower dosages, and to control moderate chronic pain in even smaller doses. The global market for this substance is significant and continues to grow. In 2022, the market was valued at US$ 138.5 million, and it is projected to reach US$ 158.3 million by 2029. This represents a compound annual growth rate (CAGR) of 1.9% during the forecast period from 2023 to 2029.
Tablets, Injection in the Global Buprenorphine Hydrochloride Market:
The Global Buprenorphine Hydrochloride Market is segmented into tablets and injections. Tablets are typically used for the treatment of opioid addiction, while injections are used for pain management. The market for both forms of Buprenorphine Hydrochloride is substantial. Europe holds the largest market share, accounting for about 31% of the global market. The largest manufacturer of Buprenorphine Hydrochloride is Siegfried, which holds about 23% of the market share. Despite the dominance of these key players, the market is highly competitive and dynamic, with numerous other players vying for a share of the pie.
Analgesic, Opioid Antagonist in the Global Buprenorphine Hydrochloride Market:
Buprenorphine Hydrochloride is used in two main areas: as an analgesic and as an opioid antagonist. As an analgesic, it is used to manage moderate to severe pain. As an opioid antagonist, it is used to treat opioid addiction. The use of Buprenorphine Hydrochloride in these areas is driven by the ongoing opioid crisis, which has increased the demand for effective treatments for opioid addiction. Furthermore, the rise in chronic pain conditions worldwide is driving the demand for effective analgesics.
Global Buprenorphine Hydrochloride Market Outlook:
To summarize the market outlook for the Global Buprenorphine Hydrochloride Market, it's important to note that the market was valued at US$ 138.5 million in 2022 and is expected to grow to US$ 158.3 million by 2029. This growth represents a CAGR of 1.9% during the forecast period from 2023 to 2029. Europe is the leading market for Buprenorphine Hydrochloride, accounting for about 31% of the global market. The largest manufacturer of Buprenorphine Hydrochloride is Siegfried, which holds about 23% of the market share.
| Report Metric | Details |
| Report Name | Buprenorphine Hydrochloride Market |
| Accounted market size in 2023 | US$ 138.5 million |
| Forecasted market size in 2030 | US$ 158.3 million |
| CAGR | 1.9% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichemlabs, Arevipharma, Resonance-labs, Sun Pharma, Rusan Pharma, Micro Orgo Chem, Faranshimi |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
